Cell-Based EC50 Determination of GPCR Agonists by cAMP HTRF Accumulation Assay in CHO-K1 Cells

Agonists are tested over a 10-point, half-log serial dilution from 10 µM to 0.3 nM final, in technical triplicate per plate across 3 independent biological replicates (separate cell passages on separate days). A reference full agonist and forskolin (receptor-independent maximal cAMP) are included on every plate. Cells are seeded at 5,000 cells/well in low-volume 384-well plates. IBMX (phosphodiesterase inhibitor) is included to preserve cAMP. Plate layout randomizes compound columns to mitigate positional effects.

BSL-1 mammalian cell culture in a Class II biosafety cabinet. Forskolin and test compounds are potential irritants/biologically active — handle in the hood and avoid aerosols. IBMX is a hazardous substance (harmful if swallowed); wear nitrile gloves, lab coat, and safety glasses. Trypsin-EDTA and selection antibiotics (G418 is harmful) require gloves. Aspirate media into a vacuum trap with disinfectant. Dispose of cell waste as biohazard and chemical waste per EHS.

Positive control: forskolin at 10 µM directly activates adenylyl cyclase, defining maximal achievable cAMP independent of the receptor. Reference agonist full dose-response defines 100% receptor-mediated Emax for normalization and partial-agonist classification. Vehicle control: buffer with matched DMSO (<= 0.5%) defines basal cAMP. Untransfected parental CHO-K1 cells serve as a receptor-specificity control to exclude endogenous-receptor or off-target cAMP responses. cAMP standard curve enables absolute quantification per plate.

A robust assay gives a forskolin/basal cAMP window of at least 10-fold and Z' >= 0.5. Reference full agonist EC50 typically lies in the nanomolar range; the concentration-response is fully sigmoidal with a defined top and bottom. Partial agonists plateau at 30-80% of reference Emax. Hill slopes are typically 0.8-1.2. Untransfected CHO-K1 cells should show no agonist-evoked cAMP (flat response).

• CHO-K1 cells stably expressing the target GPCR, mycoplasma-free
• Growth medium: Ham's F-12 + 10% FBS + 1% penicillin/streptomycin + selection antibiotic (e.g. 400 µg/mL G418)
• cAMP HTRF detection kit (cAMP-d2 conjugate + anti-cAMP-cryptate antibody + lysis/detection buffer)
• Stimulation buffer: HBSS + 20 mM HEPES pH 7.4 + 0.1% BSA + 500 µM IBMX
• Forskolin, 10 mM in DMSO
• Reference full agonist, 10 mM stock
• Test compounds, 10 mM in DMSO
• cAMP standard curve calibrator
• White, low-volume 384-well tissue-culture plates

To determine the agonist potency (EC50) and maximal efficacy (Emax) at a recombinant Gs-coupled G-protein-coupled receptor expressed in CHO-K1 cells, using competitive HTRF detection of intracellular cAMP. This cell-based functional assay enables ranking of agonists, classification of full versus partial agonists relative to a reference, and provides EC50 values suitable for lead optimization in a receptor-pharmacology campaign.

1. Harvest CHO-K1 cells (trypsin-EDTA), resuspend in stimulation buffer, and count; check viability >90% by trypan blue.
2. Dispense 5 µL of cell suspension (5,000 cells) per well into 384-well plate.
3. Prepare 4x agonist dilutions in stimulation buffer (final DMSO <= 0.5%); add 2.5 µL per well.
4. Incubate 30 min at 37 C to allow cAMP accumulation (no CO2 needed in HEPES buffer).
5. Prepare cAMP-d2 and anti-cAMP-cryptate each at working dilution in lysis buffer.
6. Add 5 µL cAMP-d2 conjugate, then 5 µL anti-cAMP-cryptate to each well (this also lyses cells).
7. Cover and incubate 60 min at room temperature in the dark.
8. Read HTRF on a compatible reader: excitation 320 nm, emission 665 nm and 620 nm; compute the 665/620 ratio.
9. Convert ratios to cAMP concentration using the calibrator standard curve.

Independent variable: agonist concentration (10 points, 0.3 nM to 10 µM). Dependent variables: HTRF 665/620 ratio and derived intracellular cAMP concentration; normalized response (% of reference Emax). Controlled variables: cell number per well, passage range, IBMX concentration, stimulation time and temperature, DMSO concentration, detection incubation time, and reader settings.

Activation of the Gs-coupled receptor by an agonist will stimulate adenylyl cyclase in a concentration-dependent manner, increasing intracellular cAMP and producing a sigmoidal concentration-response curve. We hypothesize that test agonists differ in both potency (EC50) and intrinsic efficacy (Emax) relative to the endogenous/reference full agonist, with partial agonists reaching a lower plateau even at saturating concentrations.

Interpolate HTRF ratios to cAMP (nM) from the per-plate standard curve. Normalize each compound response to the reference-agonist span: 0% = vehicle basal, 100% = reference Emax. Fit normalized concentration-response to a 4PL model in GraphPad Prism to extract EC50, Emax (top), Hill slope, and bottom. Report EC50 as geometric mean +/- 95% CI and Emax as % of reference across 3 biological replicates. Classify compounds with Emax < 80% of reference as partial agonists.

1. Small forskolin window: cells over-confluent or unhealthy — use cells in log-phase, viability >90%, and within passage limit. 2. No agonist response: receptor expression lost — re-check selection antibiotic and confirm receptor by reference agonist each run. 3. Variable EC50 between days: inconsistent cell number — count carefully and use the same dispense method. 4. Compressed window / high basal: insufficient IBMX or long pre-incubation — confirm 500 µM IBMX is fresh. 5. Poor HTRF ratios: reader filters wrong or detection time too short — verify 620/665 filters and use >= 60 min incubation in the dark.

Analyze on the log scale (pEC50). Compare pEC50 and Emax across compounds by one-way ANOVA with Dunnett's correction (vs reference agonist) at alpha = 0.05. With n=3 biological replicates and typical pEC50 SD ~0.2 log units, the design has >80% power to detect ~3-fold EC50 shifts. Emax differences are tested by ANOVA on the fitted top parameters. Exclude plates with Z' < 0.4 or forskolin window < 5-fold.